Genome-wide expression profiling of 8-chloroadenosine- and 8-chloro-cAMP-treated human neuroblastoma cells using radioactive human cDNA microarray

Park, Gil Hong; Choe, Jaegol; Choo, Hyo Jung; Park, Yun Gyu; Sohn, Jeongwon; Kim, Meyoung Kon

doi:10.1038/emm.2002.27

Cited by 19 publications

(12 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies suggest that 8-Cl-cAMP, a potent analog of cAMP, induces growth inhibition in vitro and in vivo in a broad spectrum of human carcinomas, including neuroblastoma cell lines [23][24][25]29]. Although 8-Cl-cAMP has been used in clinical trials the mechanism of its action remains controversial.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have shown that 8-Cl-cAMP exerts dual anticancer activity on human SH-SY5Y cells through the inhibition of cell proliferation and the induction of apoptosis [23,24]. A study was carried out in order to clarify the overall cellular effects of 8-Cl-cAMP and 8-Cl-AD on SK-NDZ human neuroblastoma cells in a gene expression study using a cDNA microarray [25]. The obtained results indicated that the two drugs shared common gene expression down-regulation pathways, but used distinct pathways for the up-regulation of different gene clusters.…”

Section: Discussionmentioning

confidence: 99%

“…Little is known about the antitumor effects of SF and 8-Cl-AD in human neuroblastoma cell lines. With regard to 8-Cl-cAMP, only a few studies have described its dual effect on the inhibition of cell proliferation and induction of apoptosis in SH-SY5Y cells [23][24][25]. In the present work we chose human SK-N-SH cells that have previously been used as a target cell line in cell mediated cytotoxicity assays.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro

Janković¹,

Pešić

Markovic

et al. 2006

Invest New Drugs

View full text Add to dashboard Cite

To identify purine analogs that could be effective in treating neuroblastomas, we tested the anticancer properties of sulfinosine, 8-Cl-cAMP and 8-Cl-adenosine in the SK-N-SH cell line. First we examined the effects of these three agents on cell growth inhibition and cell viability by the BrdU and Sulforhodamine B assay. Treatment of SK-N-SH cells with increasing concentrations of these compounds led to a significant inhibition of cell proliferation and decrease of cell viability in a time- and dose-dependent manner at micromolar concentration (<10 microm). Treatment with a combination of sulfinosine and 8-Cl-cAMP resulted in synergistic effects on growth inhibition, cell cycle arrest and induction of apoptosis. Flow-cytometric analysis showed that 8-Cl-cAMP arrested the cells in the G0/G1 phase and sulfinosine blocked cell cycle progression at the G2/M stage, in contrast to the combined effects of both agents that did not arrest growth at any particular phase of the cell cycle. Further analysis of apoptosis induction demonstrated an increase from 17 to 24% of both early and late apoptotic cells and a very low percentage of necrotic cells. These results indicate that apoptosis was the predominant type of cell death after treatment of SK-N-SH cells with both substances, as well as with their combinations.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro

Janković¹,

Pešić

Markovic

et al. 2006

Invest New Drugs

View full text Add to dashboard Cite

show abstract

“…In fact, the A549 cell line is a human lung carcinoma cell line. Others have reported the presence of mRNA for IL-32 in Epstein-Barr virus infected lymphoma cells, 3 neuroblastoma cells, 4 and haematopoietic progenitor cells. 5 Primary human B cells, even when stimulated with IgM or anti-CD40, do not express significant IL-32.…”

mentioning

confidence: 99%

IL-32, a novel cytokine with a possible role in disease

Dinarello

Kim²

2006

Annals of the Rheumatic Diseases

154

165

View full text Add to dashboard Cite

“…The IL-32 encoding gene locus has been identified at chromosome 16p13.3 and six isoforms, IL-32α, IL-32β, IL-32γ, IL-32δ, IL-32ε, and IL-32ξ, were identified by Kim et al and Chen et al (11,12). Moreover, several studies identified the production of IL-32 in other cell types, including epithelial cells and other monocytes, as well as the presence of IL-32 mRNA in Epstein-Barr virus-infected lymphoma, neuroblastoma, and hematopoietic progenitor cells (23)(24)(25).…”

Section: Discussionmentioning

confidence: 97%

Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma

et al. 2011

View full text Add to dashboard Cite

Abstract. ) is a proinflammatory cytokine that acts as a significant pathogenetic factor in various diseases and malignancies. However, the clinical effect of IL-32 expression in renal cell carcinoma (RCC) has not previously been investigated. The aim of the present study was to examine the significance of IL-32 overexpression in localized clear cell RCC (CCRCC). We examined 112 patients with localized CCRCC who underwent nephrectomy. The clinicopathological data were obtained by retrospective review and the expression levels of IL-32 were studied by immunohistochemistry. Tumors were classified according to staining intensity (0, no staining intensity; 1, weak; 2, intermediate; 3, strong). The cases with staining intensities from 0 to 2 comprised the IL-32 low-expression group (LEG), whereas those with a staining intensity of 3 comprised the IL-32 high-expression group (HEG). Correlations between IL-32 expression and clinicopathological parameters were determined. Staining intensities were determined for all cases as follows: 26 cases (23.2%) (score 0), 43 cases (38.4%) (score 1), 31 cases (27.7%) (score 2) and 12 cases (10.7%) (score 3). IL-32 HEG exhibited a higher recurrence rate compared to the IL-32 LEG (50 vs. 13%, P= 0.001). For survival rates, the 5-year recurrence-free survival (RFS), disease-specific survival (DSS) and overall survival (OS) rates were lower in the IL-32 HEG group compared with the IL-32 LEG group (RFS, P= 0.001; DSS, P<0.001; OS, P= 0.026, respectively). Univariate analyses revealed that Fuhrman nuclear grade and a high IL-32 expression were significant prognostic factors for predicting RFS, DSS and OS in CCRCC, whereas multivariate analyses indicated that Fuhrman nuclear grade and high IL-32 expression were still independent risk factors. In conclusion, IL-32 overexpression was associated with high recurrence rates and low RFS, DSS and OS, indicating that it may be a novel prognostic factor for predicting outcomes in patients with CCRCC.

show abstract

Genome-wide expression profiling of 8-chloroadenosine- and 8-chloro-cAMP-treated human neuroblastoma cells using radioactive human cDNA microarray

Cited by 19 publications

References 44 publications

The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro

The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro

IL-32, a novel cytokine with a possible role in disease

Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma

Contact Info

Product

Resources

About